Shares of Veradermics (MANE) jumped about 16% on Wednesday after the company released positive topline results from a Phase 2 study of its lead drug candidate, VDPHL01, for female pattern hair loss. The data validate the design of an upcoming registrational trial, which is expected to read out in the future. The stock traded at $127.00 as of midday, reflecting a 15.28% gain.
Mid-stage trial results boost confidence
The Phase 2 study evaluated VDPHL01 in patients with female pattern hair loss, a condition that affects millions of women. Veradermics said the results confirm the drug's potential and support moving forward with a larger, pivotal trial. The company did not disclose specific efficacy or safety data in the announcement, but the market reacted positively to the news, pushing shares to a session high near $129.29.
Market reaction and outlook
Veradermics' market capitalization now stands at several hundred million dollars, though the company remains pre-revenue with no approved products. The positive trial readout is a critical milestone for the biotech, which has been developing VDPHL01 as a topical treatment for androgenetic alopecia in women. Investors will now focus on the timing and design of the registrational study, which will be necessary for potential FDA approval. The hair loss treatment market is competitive, but VDPHL01's differentiated mechanism could carve out a niche if the pivotal trial succeeds.